Bioequivalence Study of 300 mg Gabapentin
NCT01738893
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
DRUG:
Gabapentin 300 mg
DRUG:
Gabapentin 300 mg
Sponsor
GlaxoSmithKline